Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alignment Healthcare, Inc. (NASDAQ: ALHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Medicare Advantage-focused health insurer. Alignment files annual and quarterly reports, along with current reports on Form 8-K, that describe its financial condition, operations and key developments in its Medicare Advantage business.
Recent Form 8-K filings show that Alignment uses these reports to announce quarterly financial results and share information discussed with investors and analysts. For example, the company has filed 8-Ks to furnish press releases on second and third quarter results and to outline discussions of strategy, market position and preliminary CMS Star Ratings. These filings often reference non-GAAP measures such as adjusted gross profit and adjusted EBITDA, which are defined and reconciled to the most comparable GAAP measures in accompanying tables.
Alignment’s SEC filings also provide detail on revenue sources and expenses. Condensed consolidated statements of operations list earned premiums and other revenue, along with medical expenses, selling, general and administrative expenses, and depreciation and amortization. Balance sheet information includes medical expenses payable, long-term debt and stockholders’ equity, giving investors a structured view of the company’s capital and obligations.
Through this page, users can track ongoing 8-K disclosures related to earnings releases, guidance updates, investor presentations and other material events. Filings may also reference CMS Star Ratings, membership expectations and risk factors summarized in the company’s Form 10-K and other periodic reports. Stock Titan enhances access to these documents with AI-powered tools that help explain terminology, highlight key sections and summarize lengthy filings, allowing investors to more quickly understand how ALHC reports its performance, membership trends and risk profile.
Alignment Healthcare, Inc. files a shelf registration on Form S-3 to permit offers and sales of multiple securities. The registration statement establishes a shelf under which the company and named selling stockholders may offer debt securities, preferred stock, common stock, depositary shares, warrants, purchase contracts and units from time to time after the effective date.
The prospectus states that specific terms, amounts, prices and use of proceeds (issuer receipts for primary offerings; selling stockholders receive proceeds from resales) will be disclosed in subsequent prospectus supplements and that the securities may be offered in U.S. dollars or foreign currency.
Alignment Healthcare, Inc. presents its 2025 annual overview as a fast‑growing Medicare Advantage platform focused on senior care. Health Plan Membership reached 236,300 as of December 31, 2025, up from about 13,000 at inception, supported by AVA, its proprietary data and care-management technology.
The company reported a net loss of $1.0 million for 2025 versus $128.1 million in 2024, with an accumulated deficit of $1,009.0 million. Revenue and Health Plan Membership posted five‑year compound annual growth rates of 36% and 29%, respectively, and the business now spans 45 markets across five states.
Alignment highlights a highly regulated Medicare Advantage model, extensive use of in‑house clinical teams, and significant compliance obligations under CMS, HIPAA, state privacy laws and insurance regulations. It also discloses numerous risks, including sustained net losses, reimbursement dependence on CMS, cybersecurity threats, regulatory changes and intense industry competition.
Alignment Healthcare, Inc. reported strong fourth quarter and full-year 2025 results, beating the high end of its guidance across membership, revenue, adjusted gross profit and adjusted EBITDA. Full-year revenue reached $3.95 billion, up 46.1% year-over-year, with a medical benefits ratio of 87.5%.
Adjusted EBITDA for 2025 was $109.9 million, and income from operations turned positive at $14.8 million while net loss narrowed to $1.0 million. The company guided 2026 revenue to $5.14–$5.19 billion, implying about 30%–31% growth, and expects adjusted EBITDA of $133–$163 million. Year-end cash and cash equivalents were $575.8 million, supported by $139.9 million of operating cash flow in 2025.
Mansour Adnan R. reported acquisition or exercise transactions in this Form 4 filing.
Alignment Healthcare, Inc. reported that Chief Digital Officer Adnan R. Mansour received an equity grant in the form of 23,441 restricted stock units (RSUs), each representing one share of common stock at no purchase price.
The RSUs will vest in approximately equal installments on February 4, 2027, 2028 and 2029, as long as Mansour continues to serve the company on each vesting date. This award increases his directly held equity stake and further links his compensation to the company’s long-term stock performance.
Alignment Healthcare President Dawn Christine Maroney sold 30,000 shares of common stock in an open-market transaction. The sale on 2026-02-17 was executed under a Rule 10b5-1 trading plan adopted on 05/22/2025, at a weighted-average price of $20.633 per share. After this transaction, she directly holds 997,015 shares of Alignment Healthcare common stock.
General Atlantic-affiliated funds filed an amended Schedule 13G reporting a sizable stake in Alignment Healthcare, Inc. As of December 31, 2025, General Atlantic (ALN HLTH), L.P. held 13,167,733 shares of Alignment’s Class A common stock, representing 6.6% of the outstanding shares.
Various General Atlantic entities, including General Atlantic, L.P. and several GAPCO and coinvestment vehicles, may be deemed to share beneficial ownership and voting and disposition power over these shares through their control relationships, but GA ALN is the record holder.
Alignment Healthcare, Inc. Chief Human Resources Officer Andreas P. Wagner reported a sale of company common stock on a Form 4. On February 10, 2026, he sold 22,238 shares of common stock at $20.47 per share and held 169,805 shares afterward, all directly owned.
According to the footnote, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted share units. The filing states this was not a discretionary trade by the reporting person, indicating the sale was linked to equity compensation rather than an open-market portfolio decision.
Alignment Healthcare reported that JEK Trust, of which Chief Executive Officer and director John E. Kao is trustee, sold 180,000 shares of the company’s common stock on 02/10/2026 at a weighted-average price of $20.4853 per share under a Rule 10b5-1 trading plan adopted on 03/12/2025.
After this sale, 2,652,641 shares are held indirectly through JEK Trust and 1,568,379 shares are held directly. The sale price reflects multiple trades in a range from $20.23 to $20.66 per share.
Wellington Management Group and affiliates report a significant institutional stake in Alignment Healthcare, Inc. They beneficially own 14,070,893 shares of Alignment Healthcare common stock, representing about 7.3%–7.34% of the class as of 12/31/2025.
The shares are owned of record by clients of various Wellington investment advisers, while the Wellington entities report shared voting and shared dispositive power over most of these shares and no sole power. They state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Alignment Healthcare.
Alignment Healthcare, Inc. filed a notice of proposed sale of 22,500 shares of its common stock under Rule 144. The planned sale through E-Trade Finance has an aggregate market value of $489,375 and is targeted for around February 10, 2026 on the Nasdaq Stock Market.
The seller previously acquired 38,941 common shares on February 7, 2024 as a stock award under the company’s 2021 Equity Incentive Plan. Shares outstanding were 200,091,742 at the time referenced, providing context for the scale of the planned sale.